ENZO BIOCHEM

 ENZのチャート


 ENZの企業情報

symbol ENZ
会社名 Enzo Biochem Inc. (ENZO BIOCHEM)
分野(sector)   
産業(industry)   
業種 ヘルスケア施設_サ―ビス   医療関連(Health Care)
概要 エンゾ・バイオケム(Enzo Biochem Inc.)は、製品・サービスを生産する技術力を提供することに重点を置くバイオサイエンス企業である。同社のセグメントには、Enzo Clinical Labs、Enzo Life Sciences及びEnzo Therapeuticsがある。Enzo Clinical Labsは、医師、医療センター、ほかの臨床ラボ、製薬企業に臨床サービスを提供する臨床基準研究所である。同セグメントは分子及びほかの臨床検査または検査のメニューも提供する。Enzo Life Sciencesは、臨床研究、医薬品開発、バイオサイエンス研究の顧客に製品とツールを製造、開発、販売する。Enzo Therapeuticsは、胃腸、感染、眼科及び代謝疾患の領域で複数のアプローチを開発するバイオ医薬ベンチャーである。開発パイプラインの製品には、多様な女性の健康感染症の検出、ほかの市場の病原体の同定に使用するための一連のアッセイが含まれる。  エンツォ・バイオケムは、米国の生命科学・バイオ会社。研究道具、診断法、治療法、サ―ビスに焦点を当てた秘伝や他のテストサ―ビスを医学界に提供する。事業は、臨床研究所、生命科学、治療薬に分かれる。医薬品開発と臨床研究の顧客に製品やツ―ルを開発・販売・製造のほか胃腸・感染・眼科疾患や代謝性疾患の分野でのアプロ―チを開発する。  Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem's products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
本社所在地 527 Madison Ave New York NY 10022 USA
代表者氏名 Barry W. Weiner
代表者役職名 President Chief Financial Officer Principal Accounting Officer Treasurer Director
電話番号 +1 516-755-5500
設立年月日 27973
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 503人
url www.enzo.com
nasdaq_url
adr_tso
EBITDA (百万ドル) -14.81300
終値(lastsale)
時価総額(marketcap)
時価総額 (百万ドル) 147.39300
売上高 (百万ドル) 90.67200
企業価値(EV) (百万ドル) 109.87900
当期純利益 (百万ドル) -22.07010
決算概要 BRIEF: For the six months ended 31 January 2019 Enzo Biochem Inc. revenues decreased 23% to $40.6M. Net loss increased from $1.5M to $14.4M. Revenues reflect Clinical Labs segment decrease of 31% to $26.3M Products segment decrease of 3% to $14.3M. Higher net loss reflects Clinical Labs segment loss totaling $8M vs. income of $2.3M Products segment income decrease of 69% to $265K Other segment loss increase of 5% to $6.7M.

 ENZのテクニカル分析


 ENZのニュース

   Harbert Discovery Fund Issues Letter to the Independent Directors of Enzo Biochem, Inc.  2021/10/27 14:44:00 Intrado Digital Media
BIRMINGHAM, Ala., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Harbert Discovery Fund demands the Board engage in genuine discussions with shareholders who have nominated director candidates in order to avoid the excessive expenses of a contested election.
   VIEX Capital Advisors LLC Buys Shares of 1,498,902 Enzo Biochem, Inc. (NYSE:ENZ)  2021/10/25 13:40:41 Dakota Financial News
VIEX Capital Advisors LLC bought a new stake in Enzo Biochem, Inc. (NYSE:ENZ) during the second quarter, Holdings Channel.com reports. The institutional investor bought 1,498,902 shares of the medical research companys stock, valued at approximately $4,752,000. Enzo Biochem makes up about 3.4% of VIEX Capital Advisors LLCs investment portfolio, making the stock its 6th biggest []
   Enzo Biochem Expands GoTestMeNow Online Portal to Provide Patients with Direct Access to Private Testing for Sexually Transmitted Infections  2021/10/21 12:38:00 Intrado Digital Media
   Bradley L. Radoff Issues Open Letter to Recently-Appointed Independent Directors of Enzo Biochem  2021/10/19 11:00:00 Business Wire
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff, who together with his affiliates holds approximately 7.2% of the outstanding common shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today issued the following open letter to Dr. Mary Tagliaferri and Dr. Ian B. Walters, who joined the Companys Board of Directors (the Board) in November 2020: Dr. Tagliaferri and Dr. Walters, As you likely know, I am one of Enzos largest shareholders and have recently nominated two highly-qualifi
   Enzo Biochem, Inc. (NYSE:ENZ) reported GAAP net income in Q4 2021 Vs net loss in the year-ago quarter  2021/10/13 16:49:28 FXDailyReport
Enzo Biochem, Inc. (NYSE:ENZ) stock fell 0.53% (As on Oct 13, 12:25:40 AM UTC-4, Source: Google Finance) though the company in the fourth quarter of The post Enzo Biochem, Inc. (NYSE:ENZ) reported GAAP net income in Q4 2021 Vs net loss in the year-ago quarter appeared first on FXDailyReport.Com .
   Alpha-Fetaprotein Testing Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:Abbott, AdnaGen, Enzo Biochem, Epigenomics, Exact Sciences, Fujirebio, Gen-Probe, Appl  2021/07/25 15:26:28 Jumbo News
This report studies the Alpha-Fetaprotein Testing Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Alpha-Fetaprotein Testing market segmented by company, region, type []
   Enzo Biochem (ENZ.NYSE) Receives FDA EUA for Rapid Extraction Method On Proprietary Test System  2021/07/20 16:38:47 Equity Guru
Enzo Biochem (ENZ.NYSE), a leading bioscience and diagnostic company, announced today that it has received an expansion of its FDA Emergency Use Authorization (EUA) for the Companys rapid extraction method on its proprietary test system for the detection of coronavirus SARS-CoV-2, including the genetic variants currently proliferating globally. One of the most important considerations in [] The post Enzo Biochem (ENZ.NYSE) Receives FDA EUA for Rapid Extraction Method On Proprietary Test System appeared first on Equity.Guru .
   Enzo Biochem shares rise on FDA EUA expansion for SARS-CoV-2 test  2021/07/20 12:41:10 Seeking Alpha
   ENZO BIOCHEM RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR RAPID EXTRACTION METHOD ON PROPRIETARY TEST SYSTEM FOR DETECTION OF CORONAVIRUS SARS-CoV-2  2021/07/20 12:00:00 Benzinga
NEW YORK, NY, July 20, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ ) ("Enzo" or the "Company"), a leading biosciences and diagnostics company, announced today that it has received an expansion of its FDA Emergency Use Authorization (EUA) for the Company''s rapid extraction method on its proprietary test system for the detection of coronavirus SARS-CoV-2 including the genetic variants that are now proliferating globally. The EUA enables laboratories to immediately use Enzo''s faster extraction process to reduce the time by over one hour, or more than 25%, enabling more test runs on a single instrument. The rapid extraction method can be used on platforms including Enzo''s proprietary GENFLEX® automated high-throughput platform, Qiagen''s QIAsymphony® SP lower-throughput platform and Enzo''s manual workflow. The AMPIPROBE® SARS-Cov-2 Test System includes three components: sample collection, AMPIXTRACT SARS-CoV-2 Extraction Kit for sample processing, and AMPIPROBE® SARS-CoV-2 Assay Kit for detection and analysis.
   Enzo Biochem Announces Online Service with TrustAssure to Schedule Timely PCR Testing Required for International Travel  2021/06/15 16:00:00 Intrado Digital Media
Testing will be available through CLX Healths TrustAssure Global Testing Platform for international travelers from New York and New Jersey who will need to complete testing immediately prior to travel.
   8 Stocks Moving In Monday's After-Hours Session  2021/03/15 17:16:00 Benzinga
Gainers Enzo Biochem (NYSE: ENZ) shares are trading higher after the company reported Q2 EPS and sales results were higher year over year. ISun (NASDAQ: …
   New Revoluation in Oxidative Stress Assay Market 2020 Massive Growth & Scope by 2020-2027 Focusing Top Players : SolarReserve BioVision, Inc. ,Enzo Biochem ,Merck and Co., Inc & More.  2020/11/12 11:30:27 OpenPR
Oxidative Stress Assay Market report is to provide accurate and strategic analysis of the Profile Projectors industry. The report closely examines each segment and its sub-segment futures before looking at the 360-degree view of the market mentioned above. Market forecasts
   Reversine Market Increased International Trade Opening New Opportunities by 2020-2025 | Merck, STEMCELL, Cayman Chemical, Creative Enzymes, Selleck Chemicals, Axon Medchem, Enzo Biochem  2020/10/27 10:54:40 OpenPR
This report provides in-depth study on the current state of the Global Reversine Market 2020-2025. Key players in the Global Reversine Market have been identified through the secondary research and their market share has been determined through primary and secondary
   Global Oxidative Stress Analysis Market 2020 Future Estimations with Top Key Players - Abcam, Cell Biolabs, Qiagen NV, Enzo Biochem, Biovision  2020/10/16 10:19:41 OpenPR
The most recent market research study titled Global Oxidative Stress Analysis Market 2020 by Company, Regions, Type and Application, Forecast to 2025 offers a concise study on the market to illustrate valuable insights related to significant market trends. The report spotlights
   The Daily Biotech Pulse: Patent Award For Theratechnologies, Enzo Biochem's Q4, Codiak Debuts  2020/10/14 11:53:08 Benzinga
Here's a roundup of top developments in … Full story available on Benzinga.com

 関連キーワード  (ヘルスケア施設_サ―ビス 米国株 ENZO BIOCHEM ENZ )

 twitter  (公式ツイッターやCEOツイッターなど)